Clin Rheumatol. 2023;43(3):1053–1061 doi: 10.1007/s10067-023-06834-y
Retrospective matched cohort study concludes that PsA is associated with increased risk of uveitis, with past uveitis and treatment with etanercept being independently associated with a higher risk of uveitis. Patients who developed uveitis were mainly treated with topical glucocorticoids.
Uveitis is the most common ocular involvement associated with PsA, having a crucial impact on quality of life, disease outcomes, and treatment decisions. To date, few data exist to support whether biologic agents prevent the occurrence of uveitis flares in the PsA population.
To this end, Hijazi, et al. carried out a retrospective matched cohort study to assess the frequency of uveitis in patients with PsA in the era of biologics and identify risk factors associated with uveitis.